Clinical Trial Search

Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2

Primary: Maximum Symptom Days/14 Days — 2.7 days

Primary: GPA — 2.75; 2.61; 3.25; 2.50 GPA(unweighted)

Primary: Asthma Control as Determined by Test for Respiratory and Asthma Control in Kids Assessment Tool — 70; 75; 85; 80 score on a scale

Primary: Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period — 50.45; 49.75 percentage of days — p=0.63

Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032

Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510

Primary: Symptom Days — 6.24; 4.82 symptom days over past 14 days — p=0.06

Primary: Number of Symptom Free Days — 10.7; 11.6 Days

Primary: Absenteeism, End of Study — 3.83; 4.41; 3.68 percentage of days enrolled

Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38

Primary: Participants Experiencing an Asthma Exacerbation That Requires Systemic Corticosteroid Therapy — 22; 20; 25; 36 participants — p=0.066

Primary: Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study — 202; 406; 26; 55 Participants

Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change

Primary: The Medication Treatment Step Assigned — 4.03; 4.05 score on a scale

Primary: Rate of Exacerbations Requiring Systemic Corticosteroids — 0.97; 0.95 events per years of follow-up

Primary: Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma…

Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days

Primary: Change in Number of Days Per Week, in the Previous 4 Weeks, of Daytime Asthma Symptoms From Baseline to 7-month Follow-up — -3.4; -2.8 days per week

Primary: Asthma Responsibility Questionnaire Change From Baseline to 8 Weeks — 2.72; 2.72; 2.79; 2.31 score on a scale

Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale

Primary: Exhaled Nitric Oxide (FeNO) Level — 29.3; 23.3 ppb

Primary: PROMIS Asthma Impact Scale (v1.0, SF8a) — -7.8; -9.3; -11.9 T-score

Primary: Characterize Contribution of Histamine in Children With Asthma — 11253.24; 6464.20; 3539.67 flux units on a continuous scale

Primary: Change in Pulmonary Asthma Score (PAS) — 0.9; 0.4 mean PAS score

Primary: Percentage of Participants From Each Stratum Who Demonstrated Correct Use of the ELLIPTA DPI at Visit 2, Attempt 1 (Day 28) — 92; 93 Percentage of participants

Primary: Diagnosis Rate of Asthma — 54; 87 Participants

Primary: Patient Quality of Life (QOL), Compared Mean QOL Change From Baseline at Each Follow-up Assessment Between the Clinics Assigned to the Intensive and Standard e-AT…

Primary: Maximal Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Following Exercise Challenge at Week 4 — -9.5; -12.7 Percent change — p=0.021

Primary: Adenosine Challenge Test — 18.46; 142.61 mg/ml